Start here if you're new
what it is
Inspire sells an implanted device that keeps your airway open at night when CPAP has already failed you.
how it gets paid
Last year Inspire Medical made $912M in revenue. inspire therapy system implants was the main engine at $748M, or 82% of sales.
why it's growing
Revenue grew 13.6% last year. 84.9% gross margin mattered most because it says the product still prints strong unit economics even while the market argues about coding and growth.
what just happened
Latest results showed revenue of $643M, up 186% vs. prior year, but EPS slipped 9% to $0.31.
At a glance
B+ balance sheet — decent shape, but not bulletproof
20/100 earnings predictability — expect surprises
90.4x trailing p/e — you're paying up for this one
8.0% return on capital — nothing to write home about
xvary composite: 42/100 — below average
What they do
Inspire sells an implanted device that keeps your airway open at night when CPAP has already failed you.
This business wins because it does one very specific thing that is hard to copy: it has treated more than 90,000 patients as of 12/31/24. Scale → more trained doctors and hospital relationships → so what: your next implant is more likely to be Inspire, not a newer rival. If your therapy depends on surgeon training and referral habits, being first at scale matters more than having a prettier slide deck.
How they make money
$912M
annual revenue · their business grew +13.6% last year
inspire therapy system implants
$748M
patient support and physician training
$64M
hospital accessories and replacement components
$55M
sleep diagnostics and other services
$45M
The products that matter
implantable neurostimulation therapy
Inspire therapy
$912M revenue · 100% of sales
it's the entire business, generating all $912M in revenue from one sleep apnea therapy for patients who cannot tolerate CPAP. when you buy INSP, this is what you own.
one-product story
Key numbers
$912M
annual revenue
This proves Inspire is past the concept stage. You are looking at a real device business, not a science project.
84.9%
gross margin
Gross margin → money left after making the product → so what: the device economics are excellent if demand holds.
90.4x
trailing p/e
You are paying 90.4 years of trailing earnings for one share. That price assumes growth keeps showing up.
10.0%
operating margin
Operating margin is still modest versus the 84.9% gross margin, which tells you sales and expansion costs are doing the heavy lifting.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- net profit margin 5.8% — keeps 6 cents of every dollar in revenue
- return on equity 8% — $0.08 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in INSP 3 years ago → it's now worth $3,200.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Latest results showed revenue of $643M, up 186% vs. prior year, but EPS slipped 9% to $0.31.
The quarter showed the weird split you should care about: sales surged, but earnings did not keep pace. Gross margin stayed strong at 84.9%, so the issue is below gross profit, where spending and reimbursement friction matter.
$643M
revenue
$0.31
eps
84.9%
gross margin
the number that mattered
84.9% gross margin mattered most because it says the product still prints strong unit economics even while the market argues about coding and growth.
-
shares of inspire medical systems have been volatile since our november report.
-
in fact, they have pulled quite the round trip.
-
following the november 3rd release of third-quarter earnings that included positive commentary regarding the safety and enhanced performance of its inspire v system, insp stock closed 15% higher at just over $85 a share.things really heated up during thanksgiving week when the stock vaulted toward its eventual high above $145, ahead of the centers for medicare & medicaid services’ (cms) announcement of changes to 2026 medical procedure reimbursement rates that stand to benefit inspire.
-
alas, that’s when the good news ended.
-
inspire medical systems soon became the subject of a securities fraud class action lawsuit.the lawsuit alleges that the company misled investors during the inspire v device launch by concealing critical operational failures. these include medicare billing software issues that prevented implanting centers from processing claims until july 1, 2025 (effectively a sixmonth delay), as well as a previously undisclosed inventory glut of earlier generation inspire iv devices that inhibited traction of inspire v during launch.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is cms reimbursement and billing friction during the inspire v rollout.
med
one therapy funds the entire company
100% of the company's $912M revenue comes from Inspire therapy. There is no second engine if procedure volumes slow, competition improves, or physician adoption stalls.
Impact: every operating issue touches the full revenue base, not a side segment.
med
billing software problems can delay real cash generation
The lawsuit alleges implanting centers could not process Medicare claims until July 1, 2025 because of billing software issues. A therapy can be clinically sound and still hit a wall if providers cannot get paid.
Impact: reimbursement friction can slow placements, collections, and sentiment at the same time.
med
Inspire V adoption has to outrun old inventory
The same allegations point to an inventory glut of Inspire IV devices that inhibited Inspire V traction during launch. That's the kind of operational problem that turns a product upgrade into a channel clean-up exercise.
Impact: if the new system does not gain clean traction, the premium multiple loses a lot of its logic.
med
the lawsuit raises credibility risk on top of legal cost
A securities fraud class action does not just create legal noise. It also keeps investor focus on what management knew, when it knew it, and how transparent the rollout really was.
Impact: with earnings predictability at 20/100 and institutions already selling, credibility matters more here than usual.
100% of revenue depends on one therapy, and with only a 4.5% net margin there is not much room for execution mistakes.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
proof that reimbursement friction is actually behind them
The market already knows about the July 1, 2025 claims-processing date. What matters next is whether billing stays smooth enough for centers to keep implanting without delay.
risk
Inspire V traction versus legacy inventory
If older Inspire IV stock keeps getting in the way, the new product cycle is not really a new cycle. It's a cleanup job.
metric
the $1.40 FY2026 EPS estimate
That number is the street's case for recovery. If it moves down, the 90.4x trailing multiple gets a lot harder to defend.
trend
institutional flow
217 institutions sold versus 159 buyers in 3Q2025. For a story this execution-sensitive, you want sponsorship improving, not leaking.
Analyst rankings
short-term outlook
below average
momentum score 4 — in human-speak, analysts think the next stretch could stay messy.
risk profile
below average
stability score 4 — this is a bumpier stock than most, and the 5 / 100 price stability score backs that up.
chart momentum
average
technical score 3 — the chart is not flashing a strong reversal or a clean breakdown. It is just unresolved.
earnings predictability
20 / 100
earnings are harder to model here than in steadier medtech names. the quarterly path from -$0.12 to $0.58 tells you why.
source: institutional data
Institutional activity
institutions have been net selling for 2 consecutive quarters — 159 buyers vs. 217 sellers in 3q2025. total institutional holdings: 31.3M shares. net selling for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$54
$150
$81
current price
$102
target midpoint · +25% from current · 3-5yr high: $155 (+90% · 18% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive